Low-Dose IL-2 Therapy: A New Hope for Heart Health
Kilder
- Nature: Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature
- Nature: Immune profiling in a living human recipient of a gene-edited pig kidney - Nature
- Nature: Huge Chinese cell atlas reveals surprising immune variation among peoples - Nature
- Fiercebiotech: GSK inks a model deal in $50M bet on Noetik's cancer AI platform - Fierce Biotech
- Biospace: EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology - BioSpace
- Bioworld: Ventyx’s NLRP3 inhibitors best in class? Lilly offers $1.2B - BioWorld MedTech
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.